M.D., Section Head/PDT Lead SCCHN, GCD Oncology, Merck
Jon Cheng, M.D., is Executive Director, Oncology Clinical Research at Merck Research Laboratories (MRL) and is Section Head of Late Stage Malignancies. In this role, he oversees the clinical development of pembrolizumab in multiple solid organ tumors including head/neck and gastrointestinal malignancies, and provides strategic development of biomarkers for immunotherapy. Dr. Cheng joined Merck in 2008 after 11 years at Fox Chase Cancer Center, where he continues to see patients as an Adjunct Professor. He had previous responsibilities at Merck developing novel combinations within the Merck pipeline, incorporating biomarkers and companion diagnostic development into clinical trials, and led a number of registrational activities.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Undeniably, cancer immunotherapy is one of the most promising areas in cancer research. New clinical trial approaches are under way to advance immune therapies for cancer. We will hear from both industry and medical representatives about their novel and innovative programs, which have the goal of expediting immunotherapy cancer treatments and delivering better patient outcomes.